FibroGen Inc (MEX:FGEN)

MXN 20.14 0.53 (2.7%) Market Cap: 2.06 Bil Enterprise Value: 1.56 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

Q1 2024 FibroGen Inc Earnings Call Transcript
May 06, 2024

MXN20.25 (-6.98%)

Earnings
Q4 2023 FibroGen Inc Earnings Call Transcript
Feb 26, 2024

MXN30 (-20.09%)

Earnings
FibroGen Inc KOL Investor Event Series Part I (Virtual) Transcript
Feb 13, 2024
Q3 2023 FibroGen Inc Earnings Call Transcript
Nov 06, 2023

MXN15.08

Earnings
Q2 2023 FibroGen Inc Earnings Call Transcript
Aug 07, 2023

MXN31 (-90.91%)

Earnings
FibroGen Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
FibroGen Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Q1 2023 FibroGen Inc Earnings Call Transcript
May 08, 2023

MXN341.2

Earnings
Q4 2022 FibroGen Inc Earnings Call Transcript
Feb 27, 2023

MXN461.5

Earnings
FibroGen Inc at Bank of America Biotech SMID Cap Conference Transcript
Dec 08, 2022
Q3 2022 FibroGen Inc Earnings Call Transcript
Nov 07, 2022

MXN350.5

Earnings
Q2 2022 FibroGen Inc Earnings Call Transcript
Aug 08, 2022

MXN251

Earnings
Q1 2022 FibroGen Inc Earnings Call Transcript
May 09, 2022

MXN257.5

Earnings
Q4 2021 FibroGen Inc Earnings Call Transcript
Feb 28, 2022

MXN314

Earnings
Q3 2021 FibroGen Inc Earnings Call Transcript
Nov 09, 2021

MXN246 (-8.21%)

Earnings
Q2 2021 FibroGen Inc Earnings Call Transcript
Aug 09, 2021

MXN278 (+0.36%)

Earnings
FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
FibroGen Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 04, 2021
FibroGen Inc Annual Shareholders Meeting Transcript
May 26, 2021
FibroGen Inc at Bank of America Global Research Healthcare Conference (Virtual) - Fireside Chat Transcript
May 13, 2021
Q1 2021 FibroGen Inc Earnings Call Transcript
May 10, 2021

MXN386.14 (-6.25%)

Earnings
FibroGen Inc Provides Additional Information on Roxadustat - Conference Call Transcript
Apr 06, 2021
FibroGen Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 02, 2021
Q4 2020 FibroGen Inc Earnings Call Transcript
Mar 01, 2021

MXN1037

Earnings
FibroGen Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 25, 2021
FibroGen Inc at Jefferies Virtual London Healthcare Conference Transcript
Nov 19, 2020
Q3 2020 FibroGen Inc Earnings Call Transcript
Nov 05, 2020

MXN1012

Earnings
FibroGen Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
FibroGen Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2020
Q2 2020 FibroGen Inc Earnings Call Transcript
Aug 06, 2020

MXN987

Earnings
FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2020
FibroGen Inc Annual Shareholders Meeting Transcript
Jun 04, 2020
FibroGen Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2020
FibroGen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Q1 2020 FibroGen Inc Earnings Call Transcript
May 07, 2020

MXN900

Earnings
Q4 2019 FibroGen Inc Earnings Call Transcript
Mar 02, 2020

MXN800 (-2.91%)

Earnings
FibroGen Inc at Leerink Global Healthcare Conference Transcript
Feb 25, 2020
Q3 2019 FibroGen Inc Earnings Call Transcript
Nov 11, 2019

MXN645

Earnings
Q2 2019 FibroGen Inc Earnings Call Transcript
Aug 08, 2019

MXN740

Earnings
FibroGen Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 12, 2019
Q1 2019 FibroGen Inc Earnings Call Transcript
May 09, 2019

MXN890

Earnings
Q4 2018 FibroGen Inc Earnings Call Transcript
Feb 27, 2019

MXN865

Earnings

Q2 2023 FibroGen Inc Earnings Call Transcript

Aug 07, 2023 / 09:00PM GMT

Release Date Price: MXN31 (-90.91%)

Transcript 10-Q8-K

Operator

Good day, and thank you for standing by. Welcome to the FibroGen's Second Quarter 2023 Earnings Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, David DeLucia. Please go ahead.

David DeLucia

Good afternoon, everyone. Thank you for joining today to discuss our second quarter 2023 financial and business results. I'm David DeLucia, Vice President of Corporate FP&A and Investor Relations at FibroGen. Joining me on today's call are Thane Wettig, our Interim Chief Executive Officer; Juan Graham, our Chief Financial Officer; Dr. Mark Eisner, our Chief Medical Officer; Dr. John Hunter, our Chief Scientific Officer; Chris Chung, our Senior Vice President of China Operations; and Enrique Conterno, our outgoing Chief Executive Officer.

Following our prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.